CRP and sarcopenia: Taken together, the results from the present study clearly suggest that the systemic inflammatory response might be directly involved in driving sarcopenia and poor tolerance to chemotherapy in GI cancer patients and that serum CRP levels could be used as a biomarker for selecting patients undergoing systemic chemotherapy who need FO-enriched nutrition.